bivalent recombinant covid-19 vaccine (adenovirus type 5 vector)
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05442684)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05442684 | Phase 3 | Nov 30, 2022 | Tianjin Cansino Biotechnology Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tianjin Cansino Biotechnology Inc | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1